Zastaprazan: A Comprehensive Clinical and Pharmacological Profile

I. Introduction to Zastaprazan

A. Overview of Zastaprazan as a Novel Acid-Suppressive Agent

Zastaprazan is a novel, orally administered potassium-competitive acid blocker (P-CAB) developed for the treatment and prevention of acid-related gastrointestinal disorders. It represents a new generation of acid-suppressive therapy, aiming to address limitations of existing treatments such as proton pump inhibitors (PPIs).[1] The development focus on characteristics like faster onset of action and food-independent dosing directly targets known drawbacks of PPIs, suggesting a strategic approach to capture market share by offering enhanced convenience and potentially more consistent acid control.[5] This approach is particularly relevant as the P-CAB class is positioned to offer tangible improvements in a mature acid-suppression market. By demonstrating non-inferiority to standard PPIs, with trends towards faster action, Zastaprazan aims to establish itself as a significant therapeutic option. The emphasis on food-independent dosing and rapid onset addresses patient convenience and adherence, critical factors in managing chronic acid-related conditions.

B. Developer and Originator Information

Zastaprazan was developed by Onconic Therapeutics Inc., a clinical-stage biopharmaceutical company based in South Korea.[1] Onconic Therapeutics is a subsidiary of Jeil Pharmaceutical Co., Ltd..[12] Notably, Onconic Therapeutics is distinguished as the only biotech firm in Korea to have secured regulatory approval and commercialized a new drug prior to its public listing, highlighting its research and development capabilities.[21]

C. Chemical Identity and Alternative Names